DelveInsight’s, “Chronic Hepatitis B Virus Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Chronic Hepatitis B Virus pipeline landscape. It covers the Chronic Hepatitis B Virus pipeline drug profiles, including Chronic Hepatitis B Virus clinical trials and nonclinical stage products. It also covers the Chronic Hepatitis B Virus therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Chronic Hepatitis B Virus Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Chronic Hepatitis B Virus Infection Pipeline landscape @ Chronic Hepatitis B Virus Infection Pipeline Outlook
Chronic Hepatitis B Virus Infection Overview
Hepatitis B viral infection is a serious global healthcare problem. It is a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is often transmitted via body fluids like blood, semen, and vaginal secretions. The majority (more than 95%) of immunocompetent adults infected with HBV can clear the infection spontaneously. Patients can present with acute symptomatic disease or have an asymptomatic infection that is identified during screening for HBV.
Recent Developmental Activities in the Chronic Hepatitis B Virus Infection Treatment Landscape
For further information, refer to the detailed Chronic Hepatitis B Virus Infection Drugs Launch, Chronic Hepatitis B Virus Infection Developmental Activities, and Chronic Hepatitis B Virus Infection News, click here for Chronic Hepatitis B Virus Infection Ongoing Clinical Trial Analysis
Chronic Hepatitis B Virus Infection Emerging Drugs Profile
Pradefovir is an oral liver-targeting prodrug of the HBV DNA polymerase/reverse transcriptase inhibitor adefovir, for the potential treatment of hepatitis B virus (HBV) infection. The drug is developing using Ligand’s HepDirect technology. Currently the product is in Phase III stage of development for the treatment of Chronic Hepatitis B.
RG6346 is an investigational GalXC™ RNAi therapeutic candidate in development in collaboration with Roche for the treatment of chronic HBV infection. RG6346 is designed to employ RNA interference to selectively knock down specific genes involved in the creation of HBV messenger RNA (mRNA) and the entry of the virus into liver cells. Preclinical data have demonstrated greater than 99.9% reduction in circulating HBsAg, as observed in mouse models of HBV infection. Unlike current therapies that typically provide long-term suppression of the virus, RG6346 has the potential to provide a functional cure for patients living with chronic HBV. Dicerna is currently conducting a Phase II trial of RG6346 in adult patients with chronic HBV infection.
Chronic Hepatitis B Virus Infection Pipeline Therapeutics Assessment
There are approx. 50+ key companies which are developing the therapies for Chronic Hepatitis B Virus Infection. The companies which have their Chronic Hepatitis B Virus Infection drug candidates in the most advanced stage, i.e. Phase III include, Ligand Pharmaceuticals.
Find out more about the Chronic Hepatitis B Virus Infection Pipeline Segmentation, Therapeutics Assessment, and Chronic Hepatitis B Virus Infection Emerging Drugs @ Chronic Hepatitis B Virus Infection Treatment Landscape
Scope of the Chronic Hepatitis B Virus Infection Pipeline Report
Dive deep into rich insights for drugs for Chronic Hepatitis B Virus Infection Pipeline Companies and Therapies, click here @ Chronic Hepatitis B Virus Infection Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Chronic Hepatitis B Virus Infection Mergers and acquisitions, Chronic Hepatitis B Virus Infection Licensing Activities @ Chronic Hepatitis B Virus Infection Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/